{"id":"W2808864948","doi":"10.1136/esmoopen-2018-000361","title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology; Genentech; GlaxoSmithKline; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Discontinuation; Oncology; Metastatic breast cancer; Meta-analysis; Breast cancer; Adverse effect; Neutropenia; PARP inhibitor; Population; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008005747,0.002262136,0.01539373,0.004760565,0.0004555193,0.002361034,0.001655402,0.001707245,0.003838737],"category_scores_gemma":[0.01634074,0.001153638,0.03116083,0.005540674,0.0004564973,0.001472087,0.0009986935,0.001671865,0.0003325329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002193728,"about_ca_system_score_gemma":0.002734413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006854666,"about_ca_topic_score_gemma":0.01688273,"domain_scores_codex":[0.9953923,0.002149734,0.001326409,0.0004546883,0.0005203345,0.0001565685],"domain_scores_gemma":[0.9918235,0.005794718,0.00137805,0.0001997515,0.0006795768,0.0001243807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.002272478,0.00003137383,0.001420627,0.4931093,0.4864406,0.00009902856,0.00006320504,0.0006875584,0.0002584215,0.0001420052,0.0007756554,0.01469966],"study_design_scores_gemma":[0.0007253253,0.0002313254,0.001897892,0.03224715,0.9620577,0.00008981937,0.00003480668,0.000215747,0.0001082364,0.000189523,0.002180274,0.00002218816],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002495105,0.9960991,0.0003691943,0.0001242333,0.00008923167,0.0002158757,0.000378546,0.00001555735,0.0002131542],"genre_scores_gemma":[0.08327793,0.9128528,0.001454147,0.0006810169,0.000164827,0.0006774474,0.0005781901,0.00001955213,0.0002940543],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01539373,"threshold_uncertainty_score":0.04233897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1524902586108739,"score_gpt":0.4081192647699527,"score_spread":0.2556290061590788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}